Intas Pharma appoints Nitin Patel, Dr Rupesh Rane to key leadership roles

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-06-23T15:56:57+05:30 | Updated On 23 Jun 2025 4:06 PM IST

Ahmedabad: Intas Pharmaceuticals has appointed Nitin Patel as Associate Vice President - Global Portfolio, Project & Business Development and Dr Rupesh Rane has also been named as Associate Vice President – International Business at Intas Animal Health.

Nitin brings deep expertise in project and lifecycle management, licensing and contracting, mergers and acquisitions, portfolio strategy, deal execution, and business development. Prior to joining Intas, he held roles at Thermo Fisher Scientific, Cadila Healthcare, and Claris.

"We look forward to his contributions as we continue to strengthen our global presence and uphold our purpose of creating an expression for a healthy life," Intas stated in a Linkedin post announcing Nitin appointment.

Dr. Rupesh Rane joins with over 25 years of rich industry experience across diverse segments including cattle, poultry, canine, equine, and aquaculture. He has previously worked with leading companies such as Piramal Enterprises, Lyka Labs, Zenex Animal Health, and Alivira Animal Health.

His deep understanding of international markets, coupled with proven expertise in business development, product innovation, client engagement, and strategic sales, makes him a valuable addition to Intas team.

Sharing his enthusiasm, Dr Rane commented, "Thrilled to join Intas Animal Health, where I aim to strengthen international business and deliver meaningful growth across diverse species and geographies."

Nitin Patel also expressed his excitement, saying, "I'm excited to join Intas and contribute to building a high-impact global portfolio through strategic innovation, collaboration, and seamless project execution."

Intas is a vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide. Intas is currently investing in a higher barrier to entry developments such as Biosimilar and New Chemical Entities.

intas pharmaintas pharma newsnitin pateldr rupesh ranethermo fisher scientificcadila healthcarepiramal enterpriseslyka labsappointment

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751